Regarding imatinib + trastuzumab, an early phase I dose-escalation trial across HER2/neu-overexpressing tumors explored feasibility and safety, without establishing efficacy or a role in routine HER2-positive breast cancer treatment [73]. This evidence concerns the gene ERBB2 and breast carcinoma.